Sun Pharmaceutical has won US approval to buy Ranbaxy Laboratories on condition that it sell its interest in a generic antibacterial medicine, the US Federal Trade Commission said on Friday.
In April last year, Sun Pharmaceutical had agreed to buy generic drug maker Ranbaxy from its owner Japan’s Daiichi Sankyo Co for $3.2 billion.
The Federal Trade Commission said it would allow the transaction if Ranbaxy sold its interests in generic minocycline tablets and capsules to generic maker Torrent Pharmaceuticals Ltd, which is also based in India.
According to this order, the drugs that Ranbaxy will have to divest include Terlipresslin, Rosuvastatin and Leuprorelin.
Sun Pharma will have to either divest its molecules or ask Ranbaxy to divest molecules held by it in other drug areas.
The FTC said the proposed acquisition would reduce the number of future suppliers in the markets for generic minocycline tablets.
Full Content: The Hindu
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Major App Developers Shun Apple’s New Payment Options, Citing Unfavorable Fees
May 12, 2024 by
CPI
Ex-Contractor Pleads Guilty to Rigging Bids in Wildfire Fuel Services for US Forest Service
May 12, 2024 by
CPI
UK Newspapers Warn Apple Against “Web Eraser” Feature’s Threat to Journalism
May 12, 2024 by
CPI
Microsoft Ordered to Pay $242 Million in Patent Infringement Case
May 12, 2024 by
CPI
UK Antitrust Authority Launches Formal Probe into Olink’s Sale to Thermo Fisher
May 12, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI